Connect with us

Entrepreneur

“We are terrified to say the word ‘vagina'”- the founder educating the world on reproductive health

After years of being ignored and dismissed, Golnoush Golshirazi was diagnosed with endometriosis

Published

on

Dr Golnoush Golshirazi, co-founder and CEO of ScreenMe

Vaginal health is an essential part of a woman’s overall health. Yet, misconceptions surrounding this topic often lead individuals to feel dirty or ashamed when experiencing problems.

The lack of research into vaginal health and women’s health more generally seems only to perpetuate these misunderstandings, leaving women suffering in silence.

Dr Golnoush Golshirazi knows this too well. After years of being ignored and dismissed by healthcare professionals, she was diagnosed with endometriosis.

Wanting to make a change, the now researcher and women’s health advocate built her own business and launched ScreenMe, a platform that screens for every bacteria present in the vaginal microbiome and helps women better understand their reproductive health. She sat down with us to share her story.

Hi Golnoush, could you tell us a bit more about your background?

My background is molecular biology, with a PhD in genetics.

What inspired you to create ScreenMe?

My own personal health journey was what really ignited my passion to help others in the health space. It took thousands of pounds and many years until I got my endometriosis diagnosis. I felt constantly dismissed, ignored by professionals and unable to perform at my very best.

I always remember getting my period during one of my final exams for my university degree. I literally couldn’t move from my bed, and after ringing up, the invigilators were able to bring me my exam paper at least – however, the fact that I had to sit an exam when all I could think about was the huge pain I was experiencing (and be supposed to feel ‘grateful’ for this), is something that I will always remember.

After receiving my endometriosis diagnosis, I took a look back at this long and painful journey and vowed that I wanted to work to make sure this changed for others.

I saw that I could really use my own knowledge and expertise to advance healthcare responses and assist in creating solutions that genuinely worked for people. It wasn’t just this, but the wish to create a space where people felt heard and had access to the science that can really change their life – as this was something I struggled to find and wish I had looking back.

How would you describe ScreenMe in a few words?

Wow, that is a hard one. In just a few words I would say: answers and solutions, with care. This is because ScreenMe brings cutting-edge science to those who need it, but also pairs such with professional guidance, education and genuine support, to create solutions that work for you as an individual.

What makes ScreenMe different?

ScreenMe’s main difference I would say comes from making cutting-edge science accessible to the general public and bringing together the scientific, medical and holistic field for support.

As a team of scientists, medical professionals and holistic practitioners, and experts within the women’s health space we have decades of experience between us. This allows us to separate fact from fiction and really give advice and solutions that work for our community.

In a world which is moving towards a preventative and holistic care model – our team is so passionate about this and works towards such every day. Our team is also why we focus on education and awareness. We are aware from our own experiences that so many people know so little about intimate health and its long-term implications for fertility, infection, and disease – so it is our team who have focused our strategy on first educating society on the topic.

Then people can make informed, evidenced decisions as to what care, testing or support they need (if at all). We are passionate about not trying to push the ‘hard-sell’ on our product, but empower people with the agency to make the decisions that are right for them.

In terms of technicalities. ScreenMe is the only UK-based company that provides NGS-based screening of vaginal and seminal samples for bacteria and yeast allowing identification of all species present at very high accuracy.

Do you feel there is a lack of awareness around the importance of the vaginal microbiome and vaginal health in general?

As a society we are terrified to even say the word ‘vagina’, let alone open up discussions around this or provide adequate education. Most people do not even know the difference between the vulva and the vagina; or do not know that there are actually seven holes in their intimate area (most think there are three!).

So many of the people with vaginas we see each day have no clue about the implications of the symptoms they have been experiencing, or even the basics on how to look after their intimate health. This lack of awareness also extends out into the medical community.

Vaginal ecosystem and the role of the vagina in the bigger picture of health is hardly spoken about at med school. So many concerns could be prevented or resolved if people only had access to the correct information and services – so this is honestly something that I could speak about all day.

Such a severe lack of education is why we include a free one-to-one consultation with a practitioner for each of our tests, so that results can be explained and solutions can be curated.

This is also why we have published our free online Vaginal Health Clinic on our site where we provide the latest information regarding the vaginal microbiome and how this relates to a whole host of concerns, including recurrent infection, miscarriage, IVF success, thrush, cancer risk and much more.

How do you think we could start educating people on these subjects?

For me, the two most important ways to do this is through schools and educating the healthcare system itself.

Firstly, regarding schools, it is simply not enough to learn about the reproductive organs and their very basic functions. We need to ensure that there is effective and detailed education for all genders on the many layers of health, which includes intimate health, the role of hormones, menstrual conditions and disorders, sexual health and wellbeing, menopause, fertility complications, and so much more.

Schools are such a brilliant access point to allow people to understand from an early age, how to look after themselves, how to protect their health, what symptoms to look for, and also how to interact and understand others who may be suffering from particular health concerns or conditions.

We also are really passionate about educating the healthcare community about this topic. You would be amazed at how little is often required to be learnt about intimate health and so we do a lot of work with practitioners to improve their knowledge on this topic – including webinars and broadcasts.

Vaginal health often comes with a lot of stigma. How did you find establishing your business in this sector?

We actually started focusing on women’s health care in general and it was only through listening to our community that we realised what a huge gap there was in understanding, testing, services and support for intimate health. So, while there have been barriers in this pivot, we ultimately have had a core community who are so appreciative of the work we do for them and want to hear more about vaginal health.

I think reading the many positive reviews that state how we have changed people’s lives, really keeps us motivated. However, having a business in this sector has been difficult when approaching investors.

Intimate health is not always something that people are comfortable speaking about, so it is sometimes difficult to present appropriate data on such, or have productive conversations. Yet this is something we are striving to change every day!

What obstacles have you encountered on this journey?

I guess the main obstacle I have faced is actually being a woman. We hear all the time how gender disparities reveal themselves in the workplace and in society as a whole – but I guess you never really realise the extent of this until you experience them first-hand yourself.

Particularly when looking for investment, it is difficult to always communicate some of the many struggles that women face daily, and present them as a consumer market – despite women making the majority of household health-related spending decisions!

I have even been in a room myself with an investor and my co-founder (who is a man), and the investor asked me for a tea and assumed that I was the assistant. It was only when we started the meeting and my co-founder asked me to answer the first question, that the investor realised the mistake he had made. Of course, instances like this do serve well to light a fire in my belly, but it is unrealistic to say that they aren’t sometimes difficult to navigate.

Where are you with ScreenMe now?

We are currently really focusing on our expansion of intimate health services. This has a multi-pronged approach including: providing top-quality thought leadership, providing our services globally and expanding the network with whom we work with.

Each month we are receiving more attention and onboarding more partners, practitioners, clinics and customers. We want to expand out outreach and awareness, so that intimate health is something everyone understands and makes a part of their routine check-ups. As we build momentum, we are so excited to see this future starting to take shape in front of us, even if there is still a way to go yet.

We have also recently launched our semen microbiome testing service. This is so we can help everyone with their intimate health. The semen microbiome is also really important for a range of similar reasons, including fertility, IVF success, infection risk, and risk of disease.

Further, in the case of heterosexual partners, this allows us to treat couples as a pair and prevent reinfections – as there is no use for only one person to do all of the work to optimise intimate health, when their sexual partner is doing nothing!

What are you looking to achieve with ScreenMe?

We want to achieve a world in which intimate and reproductive health is a key feature of education and research and people are able to get the testing, support and services required to improve such. It is crazy to me that we are still using swab culture methods to investigate intimate health, when this was a method devised over 100 years ago.

NGS is an available technology which provides much greater accuracy and is able to screen 100 per cent of the bacteria present, rather than a selected panel of pre-selected bacteria as used in swab culture or PCR methods.

ScreenMe works to make this technology available to everyone, so that they can understand the full context of their microbiome, rather than just get a few pieces of the puzzle. So, really what we are working towards is empowering everyone with their intimate health and at the same time seriously powering up research which is crucial for better intimate and reproductive health.

Where do you see the company in the future?

I see ScreenMe as the go-to platform for people globally when it comes to their intimate and reproductive health. I see a trustworthy, science-based place where men and women find answers, solutions, support and education with all of this leading to lower risk of non-communicable diseases across society.

I have big ambitions, so I don’t just want to see ScreenMe changing and growing in the future, but I want to see the whole of intimate health as we know it changing due to ScreenMe’s work!

Dr Golnoush Golshirazi is the co-founder and CEO of ScreenMe. She is a Cambridge graduate, scientist and entrepreneur who advocates for women’s equality within the healthcare system. 

News

Five women-led startups selected for Imperial pre-accelerator

Published

on

Five women-led startups will compete for a share of a £30,000 prize fund in Imperial’s WE Innovate final on Monday 15 June 2026.

The finalists are building businesses to tackle challenges in areas including vaccine technology, epilepsy care and the destruction of “forever chemicals”.

The WE Innovate programme, run by Imperial Enterprise Lab, is a targeted pre-accelerator open to teams led by students, recent alumni and early career researchers who identify as women.

The programme supports 25 women-led teams through six months of masterclasses, business coaching, one-to-one expert support and peer mentoring.

The top five teams will compete to win a share of the £30,000 prize fund at the WE Innovate Grand Final Showcase at Imperial on Monday 15 June 2026 from 18:00 to 21:00.

Tickets are free and available on a first-come, first-served basis.

This year’s final also marks the second year of WE Innovate National, a growing UK-wide programme that has expanded the WE Innovate model built at Imperial to other parts of the country.

Alongside Imperial, Queen’s University Belfast, Swansea University and Loughborough University are each hosting their own grand final showcases on their campuses.

The four showcases are collectively contributing to a shared national ecosystem focused on supporting women-led innovation.

WE Innovate National is set to expand to seven universities next year, supporting 175 women-led startup teams across the UK.

AlphaVectors Biotech is developing a lipid nanoparticle platform to enhance the stability of RNA vaccines at room temperatures.

Lipid nanoparticles are tiny fat-based particles used to deliver genetic medicines into the body. RNA vaccines use genetic instructions to help the immune system recognise a disease target.

Current RNA-based therapeutics rely on lipid nanoparticles that need storage at between -20°C and -80°C and high dosing. This increases distribution costs and leads to significant wastage, limiting scalability, deployment and accessibility in lower-resource markets.

AlphaVectors Biotech says its technology can lower the need for temperature-controlled supply chains, reduce costs and improve the scalability of RNA vaccines for wider deployment.

The startup is led by Dr Apanpreet Kaur, an Imperial alumnus with a PhD in chemical engineering.

Epile-X, by NeuraVance Labs, is working on a platform that could provide continuous, real-world brain monitoring for people with epilepsy.

More than 630,000 people in the UK live with epilepsy, according to the charity Epilepsy Action.

Epilepsy is a neurological condition that can cause recurring seizures. EEG, or electroencephalography, is a test that records electrical activity in the brain.

Current diagnosis relies on EEG recordings in clinical settings and patient-reported diaries, which may miss seizures that happen during daily life.

The startup says its technology combines a wearable EEG with AI-driven analysis to capture daily brain activity and support improved diagnosis and more personalised treatment decisions.

Epile-X is led by Ester D’Alterio, an innovation, entrepreneurship and management MSc graduate from Imperial.

FluoroCycle is developing technology for low-energy chemical destruction of PFAS, breaking down “forever chemicals” at 10 times lower temperatures than current incineration methods.

PFAS are synthetic chemicals found in air, water and soil. Some studies have linked exposure to them to health risks including thyroid disease, reproductive illness and cancer.

The startup aims to make PFAS destruction more affordable by providing its technology as an onsite engineered unit, allowing customers to save on energy and transport costs while cutting their carbon footprint.

FluoroCycle is led by Amanda Fogh, a research associate in Imperial’s department of chemistry.

Waypoint is building a video game controller for visually impaired players to hear and feel popular games, including Super Mario and Minecraft.

At least 2.2 billion people globally have some form of vision impairment, according to the World Health Organisation, while estimates show around 43 million people have complete blindness.

Waypoint says only 0.001 per cent of video games are fully playable for blind gamers.

The startup’s technology uses computer vision and AI to read the game screen and translate key information into sound, vibration and touch for a fully immersive experience.

The founders say it is the first game controller designed to make video games fully playable for blind players.

Waypoint is led by Bana Quronfuleh, an innovation design engineering MSc student at Imperial.

Snitch is developing an accountability-based app that allows friends to cut down their screen time together.

UK adults spend an average of 4.5 hours a day online on personal smartphones, tablets and computers, according to Ofcom’s Online Nation 2025 report.

Young adults spend more than six hours online on average. Some research suggests excessive screen use may have a negative impact on mental and physical health.

The app allows users to join accountability groups and set shared limits across their most used apps.

When one person scrolls, the group’s combined timer counts down. The founders say this helps build awareness, encourage reflection and create small behavioural shifts by making screen use a shared responsibility.

Snitch is led by Asha Bakhai, a design engineering MEng graduate from Imperial.

Continue Reading

News

Sun Pharma to acquire Organon in US$11bn deal

Published

on

Indian pharmaceutical giant Sun Pharma has agreed to buy Organon for US$11.75bn in a deal aimed at expanding its women’s health and biosimilars business.

Organon, which was spun out of Merck in 2021, has built a portfolio of more than 70 women’s health and general medicines products, including biosimilars, sold in the US and about 140 other countries.

The acquisition would give Sun Pharma a broader presence in biosimilars, which are medicines designed to be highly similar to existing biological drugs, and strengthen its position in women’s health.

Dilip Shanghvi, executive chairman of Sun Pharma, said: “Organon’s portfolio, capabilities, and global reach are highly complementary to our own, and we believe that bringing the two organizations together can create a stronger and more diversified platform.”

The companies said the combined business would generate annual revenue of US$12.4bn, operate across 150 countries and rank among the top three companies globally in women’s health.

They also said it would become the seventh largest biosimilar player.

Sun Pharma said the deal would help grow its innovative medicines business and expand its biosimilars offering.

It added that the combined company would have 18 large markets each generating more than US$100m in revenue.

Organon’s largest markets include the US, Brazil, Canada, China and countries in the European Union. The company also has six manufacturing facilities across the EU and emerging markets.

The deal follows market speculation that began on 10 April, when Indian media reported that Sun Pharma had submitted an all-cash offer for Organon.

A later report said the offer had been revised to US$13bn. Sun Pharma shares rose about 7 per cent on India’s National Stock Exchange after the announcement.

Sun Pharma said it would acquire all of Organon’s issued and outstanding shares in cash, using a combination of available cash and committed bank financing. It also estimated synergies of about US$350m within two to four years of completion.

The company said the acquisition would strengthen its cash generation, with EBITDA and cash flow set to nearly double, supporting efforts to reduce the net debt to EBITDA ratio of 2.3 times resulting from the deal. EBITDA is a measure of operating performance before certain costs are deducted.

Organon reported revenue of US$6.2bn last year and adjusted EBITDA of US$1.9bn. It also reported debt of US$8.64bn, down from US$9.5bn when it separated from Merck, and a cash balance of US$574m.

In November, Organon announced plans to sell its JADA System, designed to control and treat abnormal postpartum uterine bleeding or haemorrhage, to Laborie Medical Technologies for up to US$465m. Net proceeds from the sale will contribute to Organon’s cash balance as of 31 March 2026.

Organon will merge with a subsidiary of Sun Pharma, with Organon surviving the merger. The boards of both companies have approved the transaction.

Carrie Cox, executive chair of Organon, said: “Following a comprehensive review of strategic alternatives, our Board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders.”

The transaction is expected to close in early 2027, subject to regulatory approvals and Organon stockholder approval.

Continue Reading

News

Women’s digital health market set to reach US$5.28 billion in 2026 – report

Published

on

The women’s digital health market is set to reach US$5.28bn in 2026, up from US$4.36bn in 2025, according to a new report.

That would represent annual growth of 20.9 per cent, driven by factors including greater smartphone use among women, wider uptake of telehealth and a stronger focus on preventive care.

The report said the market could reach US$11.47bn by 2030, with projected annual growth of 21.4 per cent over the forecast period.

It also pointed to rising awareness of gender-specific health needs, expansion among digital health start-ups, growing demand for personalised healthcare, investment in femtech innovation and the spread of AI-enabled diagnostics.

Wearables linked to health apps and wider use of remote monitoring tools are also expected to play a larger role, as companies focus on more preventive and joined-up care.

Smartphone use was highlighted as a major driver because mobile apps are increasingly being used for women’s health services, from menstrual cycle tracking to pregnancy support.

The report cited Eurostat data showing that in 2023, 89 per cent of EU residents aged 16 to 74 in urban areas accessed the internet via smartphones.

The report also said companies in the sector are developing new technology aimed at improving access to more personalised healthcare.

One example it gave was a 2024 collaboration between Algorand and the Self-Employed Women’s Association to launch a digital health passport for women in India’s informal economy using blockchain technology.

Recent mergers and acquisitions were also noted. In March 2023, Maven Clinic acquired Naytal to expand its services in the UK and Europe.

North America was identified as the largest market in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Companies named as key players included Flo Health Inc, Natural Cycles, Elvie, Bellabeat, Clue by Biowink, MobileODT Ltd., Glow, Veera Health, Biowink GmbH, Ava AG, Hims & Hers Health, Inc., The Women’s Wellness Centre, Elara Health, myGynaeDoc, Maven Clinic, Kindbody, Allara Health, Tia and Hera Med Ltd.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.